Targets › IFNAR1
13 programs from 13 companies in 43 trials: 18 Phase 2, 16 Phase 3, 6 Phase 1, 3 Phase 4; Oncology, Infectious disease, Immunology; next expected readout Jan 2027.
Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. (UniProt, P17181)
Open in Phaseline: the race on IFNAR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Anifrolumab Interferon-alpha/beta receptor alpha chain antagonist | IFNAR1 | Phase 4 | Systemic Lupus Erythematosus; Systemic Sclerosis; Lupus Nephritis; Cutaneous Lupus Erythematosus … | Jan 2027 |
| PharmaEssentia | Ropeginterferon Alfa-2B (P1101) Interferon alpha/beta receptor positive modulator | IFNAR1, IFNAR2 | Phase 3 | Polycythemia Vera; Primary Myelofibrosis; Essential Thrombocythemia; Primary Myelofibrosis (PMF) … | Mar 2027 |
| Biogen | Peginterferon Beta-1A (BIIB017) Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | May 2027 |
| BriaCell Therapeutics | Interferon Alfa-2B Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 3 | Breast Cancer; Colorectal Neuroendocrine Tumor G1; Prostate Adenocarcinoma; Polycythemia Vera | Dec 2027 |
| University Hospital, Montpellier | Beta-interferons Type I interferon receptor agonist with immunomodulatory and anti-inflammatory effects | IFNAR1 | Phase 3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Jun 2031 |
| Xiamen Amoytop Biotech | Peginterferon Alfa-2B Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | Essential Thrombocythemia; Hepatitis B, Chronic; Malignant Melanoma | Sep 2027 |
| Brii Biosciences | Peginterferon Alfa-2A Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection; Chronic Hepatitis B Virus (HBV) Infection; Chronic Hepatitis b; Chronic Hepatitis B | Sep 2028 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Retlirafusp alfa Interferon alpha-2b variant that targets immune checkpoint pathways | IFNAR1 | Phase 2 | CRC (Colorectal Cancer) | Jun 2029 |
| Memorial Sloan Kettering Cancer Center | Ropeginterferon Pegylated interferon alpha | IFNAR1 | Phase 2 | Polycythemia Vera (PV) | Oct 2029 |
| Diakonos Oncology | Peginterferon Alfa-2A Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 2 | Glioblastoma (GBM) | Mar 2030 |
| M.D. Anderson Cancer Center | Recombinant Interferon Alpha 2b-like Protein Type I interferon receptor agonist | IFNAR1, IFNAR2 | Phase 1 | Stage III Hepatocellular Carcinoma AJCC v8 | Feb 2028 |
| Genrix (Shanghai) Biopharmaceutical | GR1603 Anti-IFNAR1 monoclonal antibody | IFNAR1 | Phase 1 | Lupus Erythematosus, Systemic | Jun 2028 |
| Brigham and Women's Hospital | Ropeginterferon Pegylated interferon alfa-2b with increased half-life | IFNAR1 | Phase 1 | JAK2 Mutation | Aug 2030 |
Systemic Lupus Erythematosus (6) Polycythemia Vera (3) Essential Thrombocythemia (3) Lupus Erythematosus, Systemic (2) Chronic Hepatitis b (2) Glioblastoma (GBM) (1) CRC (Colorectal Cancer) (1) Primary Myelofibrosis (1) Primary Myelofibrosis (PMF) (1) Chronic Myeloid Leukemia (1) Cutaneous T Cell Lymphoma (1) Ropeginterferon (1)
mixed (6), protein or peptide (6), antibody (1)
Diakonos Oncology (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) PharmaEssentia (1) BriaCell Therapeutics (1) AstraZeneca (1) Genrix (Shanghai) Biopharmaceutical (1) Brigham and Women's Hospital (1) University Hospital, Montpellier (1) Brii Biosciences (1) Memorial Sloan Kettering Cancer Center (1) Xiamen Amoytop Biotech (1) Biogen (1) M.D. Anderson Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.